Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 1163

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 13
Chunk 1163
---
 
  
    Interest income 
     13  
     15 
  
    Interest expense, net 
     (1,506) 
     (211)
  
    Total other (expense) income, net 
     (2,383) 
     4,727 
  
    Net income (loss) 
    $(17,802) 
    $(535)
  
    Less: Change in fair value and income impact of option liabilities 
     -  
     (5,521)
  
    Net income (loss) - diluted 
     (17,802) 
     (6,056)
  
    Basic earnings/(net loss) per share 
    $(20.53) 
    $(0.79)
  
    Diluted earnings/(net loss) per share 
    $(20.53) 
    $(8.92)
  
    Basic weighted-average common shares outstanding 
     867,096  
     669,739 
  
    Diluted weighted-average common shares outstanding 
     867,096  
     678,939 
  
    Comprehensive income (loss): 

    Foreign currency translation adjustment 
     3  
     (264)
  
    Total comprehensive income (loss) 
    $(17,799) 
    $(799)

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

CONDUIT
PHARMACEUTICALS INC.

CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(in
thousands, except share amounts)

    Shares  
    Amount  
    capital  
    deficit  
    income  
    deficit 

    Common stock  
    Additional paid-in  
    Accumulated  
    Accumulated other comprehensive  
    Total stockholders’ 

    Shares  
    Amount  
    capital  
    deficit  
    income  
    deficit 
  
    Balance at January 1, 2023 
     20  
    $-  
    $-  
    $(10,764) 
    $675  
    $(10,089)
  
    Retroactive application of Merger 
     646,244  
     6  
     (6) 
     -  
     -  
     - 
  
    Reclassification of additional paid-in-capital** 
     -